## (Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary) Government of India Ministry of Chemicals and Fertilizers Department of Pharmaceuticals National Pharmaceutical Pricing Authority

New Delhi, the 31st March, 2023

## **CORRIGENDUM**

S.O. 1582(E). — In the National Pharmaceutical Pricing Authority's notification S.O. 484(E), dated 2<sup>nd</sup> February, 2023 relating to fixation of retail price, published in the Gazette of India, Extraordinary, the Entry at Sl. No. 51 of the Table, both in Hindi & English version, be read as follows:

Instead of

SI. No.	Name of the Scheduled Formulation	Dosage form and strength	Unit	Ceiling Price (Rs.)
(1)	(2)	(3)	(4)	(5)
51	Salbutamol	Inhalation (MDI/DPI*) 100mcg/dose	1 MDI	0.44

Read as

SI. No.	Name of the Scheduled Formulation	Dosage form and strength	Unit	Ceiling Price (Rs.)
(1)	(2)	(3)	(4)	(5)
51	Salbutamol	Inhalation (MDI/DPI) 100mcg/dose	1 Dose	0.44

All the notes and other contents mentioned in the original order S.O. 484(E), dated 2<sup>nd</sup> February, 2023 shall remain same.

PN/243/111/2023/F

F. No. 8(111)/2023/D.P./NPPA-Div.-II

(Mahaveer Saini) Deputy Director (Pricing)